EV-302 / KEYNOTE-A39
2024
Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Carcinoma
In 886 patients with untreated advanced urothelial carcinoma, enfortumab vedotin + pembrolizumab improved progression-free and overall survival compared with platinum-based chemotherapy.
Result
Efficacy: PFS and OS (co-primary)HR 0.47
Below 1 favours enfortumab vedotin + pembrolizumab, above 1 favours platinum-based chemotherapy.
Event rates Enfortumab vedotin + pembrolizumab 31.5 vs platinum-based chemotherapy 16.1 months
Also reported: PFS HR 0.45; ORR 67.7% vs 44.4%.
- Subtopic
- Urothelial 1L
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Powles T, et al. N Engl J Med. 2024;390(10):875-888.doi 10.1056/NEJMoa2312117
Discussion & critique
Displaced platinum-based chemotherapy as first-line standard in advanced urothelial cancer: the largest OS gain ever shown in this setting.